A new biotech company is betting it can do something current migraine drugs cannot: stop the headaches entirely.
Vedana Therapeutics has emerged from stealth with $46 million in Series A funding, according to Endpoints News, with the goal of developing treatments that could free patients from migraines altogether. That ambition stands out because, as Endpoints notes, available migraine treatments typically only reduce how often attacks happen rather than eliminating them.
According to BioPharma Dive, the company made its debut Wednesday and is backed by Westlake. The reporting describes Vedana's approach as developing "anti-PACAP" therapies — an increasingly popular strategy for preventing migraines.
PACAP refers to a target that drugmakers have grown interested in as a route to heading off attacks before they start. By focusing there, Vedana is joining a wave of companies exploring the same biological pathway, betting it could offer more relief than existing options.
The $46 million Series A gives the startup early capital to pursue that work, though the sources do not detail a timeline, specific drug candidates, or clinical trial plans.
Why it matters: migraines affect a large number of people and current medicines often only blunt the problem, so a well-funded company aiming to eliminate attacks rather than merely reduce them could change what patients expect from treatment.